Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer Clinical Trial

Official title:

Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01721525
• Other study ID #: 12-150
• Status: Completed
• Phase: Phase 1
• First received: November 1, 2012
• Last updated: October 23, 2017
• Start date: November 2012
• Est. completion date: October 16, 2017

Study information

• Verified date: October 2017
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to develop a new induction chemotherapy regimen which is a combination of two pill drugs taken by mouth and two drugs given by vein. This is a phase I study, which means that the primary goal is to establish the recommended dose of an investigational drug when added to chemotherapy. The researchers wish to evaluate the effects, good and bad, of the investigational drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: October 16, 2017
• Est. primary completion date: October 16, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Department of Pathology at MSKCC confirmation of diagnosis of oropharynx squamous cell cancer, stage IVA/IVB, that is HPV associated.

Evidence of HPV can be p16 immunohistochemistry and/or HPV in situ hybridization positive test result on tumor tissue, either at MSKCC or other CLIA-approved lab.

• Age = 18 years of age

• Karnofsky Performance Status = 80

• Adequate organ function, as follows:

Adequate bone marrow reserve: absolute neutrophil count (ANC) = 1.5 X 109/L, platelets = 160 X 109/L, hemoglobin = 12 g/dL Hepatic: total bilirubin within normal limits (= 1.0 mg/dL); alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) = 1.5 X ULN (upper limit of normal) Renal: Serum creatinine = 1.3 mg/dL. Patients with serum creatinine > 1.3 mg/dL may be eligible if creatinine clearance (CrCl) = 55 mL/min based on the standard Cockroft and Gault formula.

• Patients of childbearing potential must have a negative serum pregnancy test within 14 days of treatment. Patients must agree to use a reliable method of birth control during and for 6 months following the last dose of study drug.

• Ability to swallow oral medication.

• Expansion Cohort only: At least one unstained slide from pre-treatment diagnostic biopsy or fine needle aspirate must be available for correlative immunohistochemistry study.

Exclusion Criteria:

• Prior chemotherapy or radiation for tonsillar or base of tongue squamous cell cancer

• History of hemolytic anemia or thalassemia

• Active infection or serious underlying medical condition that would impair the patient's ability to receive protocol treatment.

• Current therapeutic anticoagulation with Coumadin (warfarin)

• Current or prior treatment with ribavirin

• Known active Hepatitis B or C

• Any prior documented history of transient ischemic attack (TIA) or cerebrovascular accident (CVA)

• New York Heart Association (NYHA) Grade II or greater congestive heart failure

• Clinically significant peripheral vascular disease

• Inability to discontinue any of the following potent P-gp inhibitors (cyclosporine, erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital salt with quinidine, ritonavir, valspodar, verapamil) or inducers (St John's wort, rifampicin).

• Known pre-existing interstitial lung disease.

• Presence of poorly controlled gastrointestinal disorders that could affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption, or CTC grade =2 diarrhea of any etiology) based on treating physician assessment.

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck Cancer
• Head and Neck Neoplasms
• Neoplasms, Squamous Cell
• Squamous Cell Cancer

Intervention

Drug:
• Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects =75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center at Basking Ridge	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Boehringer Ingelheim, National Comprehensive Cancer Network

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum tolerated dose (For Dose Escalation Portion of the study)	of daily oral afatinib administered with standard daily weight based ribavirin and intravenous carboplatin and paclitaxel, Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.	1 year
Primary	expression of PTPN13 (For Expansion Cohort only)	To determine if a two week run-in with afatinib and ribavirin results in increased expression of PTPN13, as determined by IHC in pre and post treatment biopsies.	1 year
Secondary	safety and tolerability (toxicity)	Adverse events (AEs) will be assessed according to NCI common toxicity criteria (CTC) version 4.0. Dose Limiting Toxicity (DLT) include all toxicities of grade 3 or higher felt to be possibly, probably, or definitely related to study drug.	1 year
Secondary	objective response rate	Response and progression will be evaluated in this study using modified international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) (51). Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.	1 year
Secondary	pharmacokinetics	PK measurements will be collected from patients in the dose excalation cohort during the first cycle of therapy. The area under the curve (AUC0?8), half-life (t½), and maximum concentration (Cmax) for afatinib will be determined by noncompartmental analysis.	1 year

External Links

•   Memorial Sloan Kettering Cancer Center